6200 LOOKOUT ROAD, BOULDER, CO
Reports Second Quarter Financial Results and Provides a Business Update
Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
Enliven Therapeutics Increases Authorized Shares to 200 Million
Reports First Quarter Financial Results and Provides a Business Update
Annual Report to Security Holders
Financial Results, Press Release
Bolsters Board to Prepare for Next Phase of Development
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Registration Statement for Additional Securities
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Correspondence
Submission Upload